Cargando…
Anti‐platelet factor 4 immunoglobulin G levels in vaccine‐induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months
BACKGROUND: Anti‐platelet factor 4 (PF4) antibodies that activate platelets via FcγRIIA drive the pathophysiology of vaccine‐induced immune thrombocytopenia and thrombosis (VITT). Evolution of these antibodies and their ability to activate platelets after initial treatment remains unknown. OBJECTIVE...
Autores principales: | Montague, Samantha J., Smith, Christopher W., Lodwick, Clare S., Stoneley, Charlotte, Roberts, Matthew, Lowe, Gillian C., Lester, William A., Watson, Steve P., Nicolson, Phillip L. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066380/ https://www.ncbi.nlm.nih.gov/pubmed/35515079 http://dx.doi.org/10.1002/rth2.12707 |
Ejemplares similares
-
Antiplatelet drugs block platelet activation by VITT patient serum
por: Smith, Christopher W., et al.
Publicado: (2021) -
Analysis of preplatelets and their barbell platelet derivatives by imaging flow cytometry
por: Kemble, Samuel, et al.
Publicado: (2022) -
Platelet phosphatidylserine is the critical mediator of thrombosis in heparin-induced thrombocytopenia
por: Zlamal, Jan, et al.
Publicado: (2023) -
Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British society for haemostasis and thrombosis annual meeting
por: Whyte, Claire S., et al.
Publicado: (2023) -
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)
por: Makris, Michael, et al.
Publicado: (2021)